Distribution and drug resistance of Escherichia coli producing extended-spectrum β-lactamase

Objective To investigate the clinical distribution and drug resistance of Escherichia coli producing extended-spectrum β-lactamase (ESBLs). Methods A total of 506 Escherichia coli strains were detected in Kaifeng Central Hospital from January 2016 to December 2017. The strains were isolated from 506 inpatients with non-digestive infections. The K-B disk diffusion method was used to detect drug resistance, and phenotypic confirmatory test was used to test the producing ESBLs strains. The strains distribution were recorded and their drug resistance conditions were analyzed. Results The 506 strains of Escherichia coli were more common in the respiratory tract (40.32%, 204/506), followed by the urinary tract (21.74%, 110/506), of which 116 strains (22.92%, 116/506) produced ESBLs. Both producing ESBLs strains and non-ESBLs strains did not show obvious resistance to imipenem, ertapenem, meropenem, and tigecycline. The drug resistance rate of producing ESBLs strains to other commonly used antibiotics was higher than that of non-ESBLs strains (P<0.05). Conclusions Escherichia coli is mainly related to lower respiratory tract and urinary system infections. ESBLs-producing strains are more resistant than non-ESBLs strains. Key words: Escherichia coli; Producing extended-spectrum β-lactamase; Respiratory tract infection